Healthians, the Gurugram-based digital diagnostics company, turned profitable for the first time in FY26, reporting a net profit of ₹5.4 crore compared with a net loss of ₹4.77 crore in FY25. The milestone came as the company’s operating revenue jumped 35.7% year over year to ₹357 crore, reflecting stronger demand for its diagnostics services and improved operating efficiency.
The turnaround marks an important shift for India’s digital-first diagnostics sector, where companies have historically prioritized rapid expansion and customer acquisition over profitability. Healthians’ latest financial performance shows that revenue growth, tighter cost management and lower marketing expenditure helped it move into the black, although the company continues to carry substantial accumulated losses of about ₹976 crore.
Healthians Turns Profitable In FY26
Healthians reported its first-ever annual net profit of ₹5.4 crore in FY26.
The company had reported a net loss of ₹4.77 crore in FY25.
The improvement came despite total expenses rising during the year, indicating that revenue growth outpaced the increase in operating costs.
Healthians Financial Performance
| Metric | FY25 | FY26 |
|---|---|---|
| Operating revenue | ₹263 crore | ₹357 crore |
| Revenue growth | — | 35.7% |
| Net result | ₹4.77 crore loss | ₹5.4 crore profit |
| Total expenses | ₹275 crore | ₹364 crore |
| Diagnostics contribution | — | ~99% of operating revenue |
| Accumulated losses | — | ~₹976 crore |
The numbers point to a significant financial turnaround, although the size of the net profit remains modest compared with the company’s overall revenue base.
Revenue Jumps 35.7% To ₹357 Crore
Healthians’ operating revenue increased from approximately ₹263 crore in FY25 to ₹357 crore in FY26.
That represents growth of 35.7% in a single year.
The diagnostics business accounted for approximately 99% of operating revenue, highlighting how central laboratory testing remains to the company’s business model.
Revenue Growth
FY25
₹263 Cr
██████████████████████████
│
│ +35.7%
▼
FY26
₹357 Cr
███████████████████████████████████
The growth suggests that Healthians was able to increase testing volumes and customer activity while simultaneously improving its cost structure.
Diagnostics Remains The Core Business
Healthians operates a technology-enabled diagnostics platform focused heavily on at-home testing.
Customers can book diagnostic tests digitally, with samples collected from their homes and processed through the company’s laboratory network.
The company says it has conducted more than 10 crore tests and operates across more than 250 cities.
Healthians Business Model
Customer
│
▼
Online test booking
│
▼
Home sample collection
│
▼
Healthians laboratory network
│
▼
Diagnostic testing
│
▼
Digital report
The model combines healthcare services with technology to make diagnostic testing more convenient for consumers.
At-Home Diagnostics Is Driving Growth
The company’s growth comes as consumers increasingly use home-based healthcare services.
Healthians has positioned itself around the convenience of getting diagnostic samples collected at home rather than requiring customers to visit laboratories.
The company said more than 1 million customers used its home diagnostics services during the quarter ended June 2025, when it first announced full EBITDA and cash profitability for the quarter.
The FY26 financial results indicate that the improvement continued beyond that initial quarterly milestone.
Employee Costs Remain The Largest Expense
Employee benefit expenses were Healthians’ largest major cost category in FY26.
The company spent approximately ₹134 crore on employee benefits, an increase of around 28% year over year.
That represented about 36.8% of its total operating expenditure.
Healthians Expense Structure
| Expense | FY26 |
|---|---|
| Employee benefits | ₹134 crore |
| Materials / testing-related costs | ₹109 crore |
| Marketing | ₹44 crore |
| Total expenses | ₹364 crore |
Employee expenses cover the workforce needed to operate laboratories, technology platforms, customer services and sample-collection operations.
Marketing Spending Declines
One of the important factors behind Healthians’ profitability was a reduction in marketing expenditure.
Marketing costs fell to approximately ₹44 crore during FY26.
The decline came as the company focused more heavily on operational efficiency and organic customer growth.
Cost-Management Strategy
Revenue growth
│
├── More customers
├── Higher testing volumes
└── Broader reach
│
▼
Lower marketing intensity
│
▼
Better operating leverage
│
▼
FY26 profit
This suggests that Healthians was able to grow without increasing customer-acquisition spending at the same rate as revenue.
Expenses Rose 32.4%
Although Healthians became profitable, its total expenses still increased substantially.
Total expenses rose 32.4% from ₹275 crore in FY25 to ₹364 crore in FY26.
Revenue, however, grew faster at 35.7%.
That difference between revenue and expense growth helped the company move from a net loss to a small profit.
Revenue Vs Expenses
| Indicator | FY25 | FY26 | Change |
|---|---|---|---|
| Revenue | ₹263 Cr | ₹357 Cr | +35.7% |
| Expenses | ₹275 Cr | ₹364 Cr | +32.4% |
| Net result | -₹4.77 Cr | +₹5.4 Cr | Turnaround |
The improvement demonstrates the importance of operating leverage in Healthians’ business model.
Healthians Reached EBITDA And Cash Profitability Earlier
The FY26 annual profit follows an earlier milestone.
Healthians announced in July 2025 that it had achieved full EBITDA and cash profitability during the quarter ended June 2025.
The company described the development as an important milestone for India’s digital-first healthcare sector, where the ability to achieve sustainable profitability had been a long-standing question.
Profitability Journey
FY25
Near break-even
│
▼
Q1 FY26
EBITDA + cash positive
│
▼
FY26
₹5.4 Cr net profit
The annual results now show that the improvement was not limited to a single quarter.
Profitability Remains Modest
Despite the turnaround, Healthians’ net profit of ₹5.4 crore represents only a small fraction of its ₹357-crore operating revenue.
This means the company has moved into profitability, but its margin remains relatively thin.
Its reported EBITDA margin was approximately 2.2% during FY26.
Healthians Profitability
| Metric | FY26 |
|---|---|
| Operating revenue | ₹357 crore |
| Net profit | ₹5.4 crore |
| Approx. net margin | ~1.5% |
| EBITDA margin | ~2.2% |
The next challenge will be expanding profitability as the company continues to grow.
Accumulated Losses Remain A Major Overhang
Healthians’ first annual profit does not erase losses accumulated during its earlier expansion phase.
The company continues to carry approximately ₹976 crore in accumulated losses.
That figure illustrates how much capital the business consumed while building its technology, laboratory infrastructure and geographic network.
Profitability Vs Historical Losses
Accumulated losses
~₹976 Cr
████████████████████████████████████████
FY26 profit
₹5.4 Cr
█
The gap is substantial, meaning several years of sustained profits would be required to materially offset the historical deficit.
Healthians Has Raised Significant Capital
Healthians has received substantial backing from venture and institutional investors during its expansion.
Reports have cited cumulative funding of more than $75 million, while other company-related disclosures have referenced total capital raised above $100 million over the company’s expansion period.
Its investor base has included names such as WestBridge Capital, BEENEXT, Evolvence Fund, YouWeCan and DG Ventures.
The capital helped Healthians build laboratory infrastructure and expand its geographic footprint.
WestBridge Increased Its Bet On Healthians
In January 2026, WestBridge invested an undisclosed amount in Healthians as part of an ongoing funding round.
The transaction was also accompanied by a management transition, with founder Deepak Sahni selling a major portion of his stake to WestBridge and stepping away from executive roles.
Nishant Singhal, who had become board member and CEO in July 2025, continued to lead the company.
Healthians Leadership Transition
| Development | Details |
|---|---|
| Founder | Deepak Sahni |
| Founder transition | Moved out of executive positions |
| New leadership | Nishant Singhal |
| WestBridge | Increased investment |
| Timing | January 2026 |
The leadership transition came as Healthians moved into a new phase focused more heavily on profitability.
Healthians Has Expanded Its Laboratory Network
The company has expanded its diagnostic infrastructure substantially over the years.
Reports have cited more than 22 laboratories and a presence across roughly 250-300 cities, depending on the reporting period and definition of its service footprint.
This infrastructure supports the company’s home-collection model.
Expansion Model
Laboratories
│
▼
Sample collection network
│
▼
250+ cities
│
▼
Home testing
│
▼
Large customer base
The challenge is ensuring that this infrastructure remains efficiently utilized as the company grows.
Competition Is Intensifying
Healthians operates in a diagnostics market that includes established laboratory chains and fast-growing digital health companies.
Key competitors include Dr Lal PathLabs, Thyrocare, Redcliffe Labs and Orange Health.
The competitive landscape combines traditional diagnostic networks with newer digital-first companies offering home sample collection and online booking.
Diagnostics Competition
| Company | Broad Positioning |
|---|---|
| Healthians | Digital-first, home diagnostics |
| Dr Lal PathLabs | Large established diagnostics network |
| Thyrocare | National diagnostics platform |
| Redcliffe Labs | Diagnostics + home collection |
| Orange Health | Technology-driven diagnostics |
Healthians’ profitability milestone therefore arrives as competition for consumers and corporate wellness customers remains intense.
Healthians Is Targeting India’s Middle Class
The company has positioned affordable preventive diagnostics as a major opportunity.
CEO Nishant Singhal has said Healthians wants to serve a significant portion of India’s middle-class population by FY28, using affordable health packages and home-based testing.
The company has highlighted packages containing dozens of tests at relatively low consumer prices.
Growth Opportunity
Affordable diagnostics
+
Home sample collection
+
Digital booking
+
Preventive healthcare
│
▼
Large addressable market
│
▼
Potential volume growth
The strategy relies on generating high testing volumes while maintaining low customer-acquisition and fulfillment costs.
Scale Could Improve Unit Economics
Healthians’ FY26 results suggest that scale is beginning to work in its favor.
If revenue continues growing faster than expenses, fixed infrastructure and technology costs can be spread across a larger number of tests.
That could gradually improve margins.
Potential Operating-Leverage Cycle
More customers
│
▼
More tests
│
▼
Higher laboratory utilization
│
▼
Lower cost per test
│
▼
Better margins
│
▼
More capacity for growth
However, this cycle depends on Healthians maintaining growth without returning to high marketing expenditure.
The Company Still Needs To Prove Sustained Profitability
A single profitable financial year is an important milestone, but investors and potential future backers will likely focus on whether Healthians can remain profitable while continuing to expand.
The company’s thin net margin leaves limited room for unexpected increases in employee, laboratory, logistics or customer-acquisition costs.
Sustained profitability will therefore be more significant than the initial turnaround itself.
Digital Diagnostics Is Moving Toward Financial Discipline
Healthians’ results reflect a broader shift in India’s healthtech sector.
During the early years of digital healthcare, many companies prioritized expansion, technology development and customer acquisition.
As funding conditions became more selective, businesses increasingly focused on unit economics, cash generation and sustainable growth.
Healthians’ move into annual profitability demonstrates how that transition is affecting diagnostics.
Healthtech Business Model Shift
| Earlier Priority | Increasing Priority |
|---|---|
| Customer acquisition | Customer retention |
| Geographic expansion | Profitable expansion |
| Gross bookings | Revenue quality |
| Funding growth | Cash generation |
| Market share | Unit economics |
| High marketing spend | Efficient acquisition |
The company’s FY26 performance provides an example of this changing approach.
The Bigger Picture
Healthians’ first annual profit marks a meaningful turnaround for India’s digital diagnostics sector. The company reported ₹5.4 crore of net profit in FY26 after a ₹4.77-crore loss in FY25, while operating revenue rose 35.7% to ₹357 crore. Diagnostics accounted for roughly 99% of operating revenue, showing that the company’s core home-testing business remains the primary engine of growth.
The improvement was achieved even as total expenses increased 32.4% to ₹364 crore, with employee benefits remaining the largest cost category. Lower marketing spending and stronger operating leverage helped revenue growth outpace expenses. However, Healthians still carries accumulated losses of approximately ₹976 crore, meaning the FY26 profit is better viewed as the beginning of a potential financial turnaround rather than the completion of one.
Looking Ahead
Healthians’ next challenge will be maintaining profitability while expanding its presence across India’s diagnostics market. The company has already built a large home-collection network and says it has conducted more than 10 crore tests across more than 250 cities. If it can continue growing revenue without proportionately increasing marketing and infrastructure costs, operating leverage could gradually lift margins from their current modest levels.
The longer-term test will be whether the company can turn its first profitable year into a durable business model. Competition from established laboratory chains and digital-first rivals remains strong, while Healthians’ accumulated losses underline the capital intensity of its earlier expansion. For now, the FY26 results provide evidence that the home-diagnostics model can reach profitability at scale, provided growth is accompanied by tighter cost control and improving unit economics.
Get the day’s top stories in your inbox
One concise email. No spam, unsubscribe anytime.
